Nutromics
Nutromics is an Australian MedTech company developing a wearable Lab-on-a-Patch® diagnostic platform that combines DNA-based biosensors with microneedles to enable continuous, real-time molecular monitoring, initially targeting hospital-based vancomycin drug monitoring with FDA approval targeted for 2028.
- Company typePrivate
- Founded2019
- HeadquartersMelbourne, Australia
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nutromics does
Nutromics Pty Ltd is an Australian MedTech company developing a wearable diagnostic platform called Lab-on-a-Patch®, which combines DNA-based Electrochemical Aptamer Biosensor (EAB) sensors with microneedles to deliver continuous, real-time molecular monitoring of biomarkers via interstitial fluid access. The company positions its technology as an alternative to traditional lab-based diagnostics, which it argues provide only single data points several hours old and underpin roughly 70% of clinical decisions, an inefficiency it attributes to poor outcomes for dynamic conditions and high healthcare costs. The first commercial application is continuous therapeutic drug monitoring, with vancomycin identified as the lead analyte and FDA approval targeted for 2028.
The company operates dual hubs with headquarters in Brunswick, Melbourne, Australia (420 Victoria Street) and a US presence in San Diego, California. It is privately held, venture-backed, and reports headcount of 51–100 employees. Co-founders Peter Vranes and Hitesh Mehta serve as co-CEOs, with Agim Beshiri as Chief Medical Officer. As of the most recent disclosure, the company has raised approximately $60 million across eight funding rounds since 2018, including a $14 million pre-Series A in September 2022 led by Dexcom Ventures and a September 2025 acceleration round of A$7.5 million led by an unnamed Australian life sciences investor. Other disclosed investors include Artesian VC, VU Venture Partners, CP Ventures, and MedTech Actuator, with LaunchVic providing ecosystem support.
Nutromics is pre-revenue and pre-commercial: the Lab-on-a-Patch® product is not yet approved by the FDA or any other regulatory body and is currently in clinical development, including in-vivo trials. The go-to-market strategy, once approved, is an enterprise field-sales motion targeting hospitals and acute-care settings through clinical procurement channels. The company is evaluating locations for a state-of-the-art manufacturing facility to support future commercial production and is positioning its platform for expansion beyond vancomycin into broader continuous molecular monitoring across multiple indications.
Nutromics firmographics
Firmographics- Name
- Nutromics
- Legal name
- Nutromics Pty Ltd
- Website
- https://nutromics.com.au
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Nutromics is an Australian MedTech company developing a wearable Lab-on-a-Patch® diagnostic platform that combines DNA-based biosensors with microneedles to enable continuous, real-time molecular monitoring, initially targeting hospital-based vancomycin drug monitoring with FDA approval targeted for 2028.
- Ownership category
- akta.pro rank
Nutromics industry classification
Industry- Product category
- Wearable Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
- akta.pro secondary industries
- Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Nutromics is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Nutromics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Lab-on-a-patch diagnostic devices: Pre-revenue company developing a wearable diagnostic platform. Revenue model not yet publicly disclosed; product in clinical development with FDA approval targeted for 2028. The company is advancing commercialization of its lab-on-a-patch platform for drug monitoring.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Nutromics product offering
Product offeringCore offering
Nutromics develops a wearable diagnostic platform called Lab-on-a-Patch® that combines DNA-based electrochemical aptamer biosensors (EAB) with microneedles to enable continuous, real-time molecular monitoring of biomarkers through the skin. The company's first commercial application targets continuous therapeutic drug monitoring for vancomycin in hospital and acute-care settings, with FDA approval targeted for 2028.
Product overview
Nutromics offers a single unified product: the Lab-on-a-patch®, a wearable diagnostic platform. This platform combines DNA-based electrochemical affinity biosensing (EAB) technology with microneedles to enable continuous molecular monitoring of biomarkers. The product is currently in development and has not yet received regulatory approval. The company's first commercial application focuses on vancomycin drug monitoring, with broader applications planned across multiple medical indications and healthcare settings.
Differentiator
Problem solved
Functional benefit
Products and services
- Lab-on-a-Patch®
Quantifiable outcome
- 70% of clinical decisions rely on lab diagnostics that provide only single data points hours old
Companies that use Nutromics
Customer profileSegments2 records
Ideal customer profiles2 records
Nutromics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Nutromics partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights6 records
Nutromics competitors and assessment
Company assessmentEmerging players
- Profusa: Developer of injectable biosensor hydrogels for continuous monitoring of multiple analytes over months. Comparable in targeting continuous multi-analyte molecular monitoring outside traditional lab workflows, though using a tissue-implantable rather than microneedle approach.
- Tasso: Developer of patient-friendly microsample blood collection devices for remote diagnostics. Comparable as an emerging player in decentralized, minimally-invasive molecular monitoring, addressing the same pain point of replacing traditional venipuncture with patient- or clinician-friendly collection.
- Quanterix: Single-molecule sensitivity immunoassay platform (Simoa) used in neurology, oncology, and infectious disease diagnostics. Comparable as an emerging high-sensitivity diagnostics platform pursuing ultra-low biomarker detection, though based on lab-instrument immunoassays rather than a wearable.
- Biolinq: Developer of a microneedle patch biosensor platform for continuous intradermal biomarker monitoring. Highly comparable in form factor and minimally invasive continuous sensing approach, though focused initially on glucose/metabolites rather than therapeutic drug monitoring.
- Senseonics: Long-term implantable continuous glucose monitoring company (Eversense). Comparable in pursuing extended-duration continuous monitoring in alternative form factors (implantable vs. Nutromics' microneedle patch) with similar FDA pathway and hospital/endocrinology channel.
- RPS Diagnostics (RPS Detectors): Developer of rapid point-of-care diagnostic platforms for infectious disease and other biomarkers. Comparable as an emerging diagnostics company pursuing decentralized molecular detection outside central labs, though without a wearable/microneedle form factor.
Broad incumbents
- Medtronic: Diversified medical device leader with continuous monitoring products (Guardian CGM, LINQ insertable cardiac monitor) and deep hospital sales infrastructure. Comparable as an incumbent that could either acquire or compete with Nutromics in continuous molecular monitoring.
- Dexcom: Global leader in continuous glucose monitoring (CGM) and a strategic investor in Nutromics. Dexcom dominates wearable continuous biosensing today and is the most directly comparable incumbent in form factor, distribution, and regulatory pathway, though its chemistry is enzymatic rather than aptamer-based.
- Abbott (FreeStyle Libre / i-STAT): Market leader in continuous glucose monitoring via FreeStyle Libre and a major point-of-care diagnostics franchise through i-STAT. Comparable to Nutromics across both the wearable continuous monitoring and point-of-care molecular diagnostics categories, though at vastly larger scale and with established hospital channels.
Regional players
- EKF Diagnostics: Point-of-care and central laboratory diagnostics company with strong hospital channel presence globally. Comparable in targeting rapid decentralized diagnostics workflows, though primarily offering bench-top analyzers and reagents rather than wearable biosensors.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Nutromics social profiles
Digital presenceNutromics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nutromics leadership team
Management profileNumber of profiles
Profiles3 records
Nutromics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nutromics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nutromics
What does Nutromics do?
Nutromics develops a wearable diagnostic platform called Lab-on-a-Patch® that combines DNA-based electrochemical aptamer biosensors (EAB) with microneedles to enable continuous, real-time molecular monitoring of biomarkers through the skin. The company's first commercial application targets continuous therapeutic drug monitoring for vancomycin in hospital and acute-care settings, with FDA approval targeted for 2028.
Is Nutromics a public or private company?
Nutromics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nutromics founded?
Nutromics was founded in 2019. It employs 51 to 100 people.
Where is Nutromics based?
Nutromics is headquartered in Melbourne, Australia, in the Oceania region.
How does Nutromics make money?
One revenue line is on record: lab-on-a-patch diagnostic devices.
Who are Nutromics's main competitors?
Emerging players on record are Profusa, Tasso, Quanterix, Biolinq, Senseonics and RPS Diagnostics (RPS Detectors). Broad incumbents are Medtronic, Dexcom and Abbott (FreeStyle Libre / i-STAT). EKF Diagnostics is listed as a regional player.
Does Nutromics have an API?
No public API is recorded for Nutromics.
What industry is Nutromics in?
Nutromics's product category is Wearable Diagnostic Devices. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges). Its NAICS code is 334510 and its SIC code is 3845.